| 1 | ONCSSF2 ;Hines OIFO/GWB - SITE-SPECIFIC FACTOR 2 (165.5,44.2) ;11/20/03
 | 
|---|
| 2 |  ;;2.11;ONCOLOGY;**40**;Mar 07, 1995
 | 
|---|
| 3 |  ;
 | 
|---|
| 4 |  ;SITE-SPECIFIC FACTOR 2 (165.5,44.2)
 | 
|---|
| 5 | SSF2IT ;INPUT TRANSFORM
 | 
|---|
| 6 |  ;
 | 
|---|
| 7 |  S PS=$P($G(^ONCO(165.5,D0,2)),U,1)
 | 
|---|
| 8 |  I PS="" K X W "  No PRIMARY SITE defined for this primary" Q
 | 
|---|
| 9 |  S MO=$$HIST^ONCFUNC(D0)
 | 
|---|
| 10 |  ;
 | 
|---|
| 11 |  S SSFIEN=$S($D(^ONCO(164.52,"C",PS_"-2")):$O(^ONCO(164.52,"C",PS_"-2",0)),1:1)
 | 
|---|
| 12 |  ;
 | 
|---|
| 13 |  ;Malignant Melanoma of Skin, Vulva, Penis, Scrotum
 | 
|---|
| 14 |  I $$MELANOMA^ONCOU55(D0) D
 | 
|---|
| 15 |  .S MELIEN=$O(^ONCO(164.52,"B","ULCERATION",0))
 | 
|---|
| 16 |  .I $E(PS,3,4)=44 S SSFIEN=MELIEN Q
 | 
|---|
| 17 |  .I $E(PS,3,4)=51 S SSFIEN=MELIEN Q
 | 
|---|
| 18 |  .I $E(PS,3,4)=60 S SSFIEN=MELIEN Q
 | 
|---|
| 19 |  .I PS=67632 S SSFIEN=MELIEN Q
 | 
|---|
| 20 |  ;
 | 
|---|
| 21 |  ;Hodgkin and Non-Hodgkin Lymphomas of All Sites
 | 
|---|
| 22 |  I $$LYMPHOMA^ONCFUNC(D0) S SSFIEN=$O(^ONCO(164.52,"B","SYSTEMIC SYMPTOMS AT DIAGNOSIS",0))
 | 
|---|
| 23 |  ;
 | 
|---|
| 24 |  ;Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum
 | 
|---|
| 25 |  ;Kaposi Sarcoma of All Sites
 | 
|---|
| 26 |  I (MO=97003)!(MO=97013)!($E(MO,1,4)=9140) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
 | 
|---|
| 27 |  ;
 | 
|---|
| 28 |  ;Hematopoietic, Reticuloendothelial, Immunoproliferative, and
 | 
|---|
| 29 |  ;Myeloproliferative Neoplasms
 | 
|---|
| 30 |  I (MO'<97310)&(MO'>99899) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
 | 
|---|
| 31 |  ;
 | 
|---|
| 32 |  ;Retinoblastoma
 | 
|---|
| 33 |  I $E(MO,1,3)=951 S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
 | 
|---|
| 34 |  ;
 | 
|---|
| 35 |  I '$D(^ONCO(164.52,SSFIEN,1,"B",X)) K X Q
 | 
|---|
| 36 |  S SSF=$O(^ONCO(164.52,SSFIEN,1,"B",X,0))
 | 
|---|
| 37 |  W "  ",$P(^ONCO(164.52,SSFIEN,1,SSF,0),U,2)
 | 
|---|
| 38 | ITEX K PS,SSFIEN,SSF,MO,MELING Q
 | 
|---|
| 39 |  ;
 | 
|---|
| 40 | SSF2OT ;OUTPUT TRANSFORM
 | 
|---|
| 41 |  ;
 | 
|---|
| 42 |  S PS=$P($G(^ONCO(165.5,D0,2)),U,1)
 | 
|---|
| 43 |  Q:PS=""
 | 
|---|
| 44 |  S MO=$$HIST^ONCFUNC(D0)
 | 
|---|
| 45 |  ;
 | 
|---|
| 46 |  S SSFIEN=$S($D(^ONCO(164.52,"C",PS_"-2")):$O(^ONCO(164.52,"C",PS_"-2",0)),1:1)
 | 
|---|
| 47 |  ;
 | 
|---|
| 48 |  ;Malignant Melanoma of Skin, Vulva, Penis, Scrotum
 | 
|---|
| 49 |  I $$MELANOMA^ONCOU55(D0) D
 | 
|---|
| 50 |  .S MELIEN=$O(^ONCO(164.52,"B","ULCERATION",0))
 | 
|---|
| 51 |  .I $E(PS,3,4)=44 S SSFIEN=MELIEN Q
 | 
|---|
| 52 |  .I $E(PS,3,4)=51 S SSFIEN=MELIEN Q
 | 
|---|
| 53 |  .I $E(PS,3,4)=60 S SSFIEN=MELIEN Q
 | 
|---|
| 54 |  .I PS=67632 S SSFIEN=MELIEN Q
 | 
|---|
| 55 |  ;
 | 
|---|
| 56 |  ;Hodgkin and Non-Hodgkin Lymphomas of All Sites
 | 
|---|
| 57 |  I $$LYMPHOMA^ONCFUNC(D0) S SSFIEN=$O(^ONCO(164.52,"B","SYSTEMIC SYMPTOMS AT DIAGNOSIS",0))
 | 
|---|
| 58 |  ;
 | 
|---|
| 59 |  ;Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum
 | 
|---|
| 60 |  ;Kaposi Sarcoma of All Sites
 | 
|---|
| 61 |  I (MO=97003)!(MO=97013)!($E(MO,1,4)=9140) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
 | 
|---|
| 62 |  ;
 | 
|---|
| 63 |  ;Hematopoietic, Reticuloendothelial, Immunoproliferative, and
 | 
|---|
| 64 |  ;Myeloproliferative Neoplasms
 | 
|---|
| 65 |  I (MO'<97310)&(MO'>99899) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
 | 
|---|
| 66 |  ;
 | 
|---|
| 67 |  ;Retinoblastoma
 | 
|---|
| 68 |  I $E(MO,1,3)=951 S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
 | 
|---|
| 69 |  ;
 | 
|---|
| 70 |  S SSF=$O(^ONCO(164.52,SSFIEN,1,"B",Y,0)) I SSF="" G OTEX
 | 
|---|
| 71 |  S Y=$P($G(^ONCO(164.52,SSFIEN,1,SSF,0)),U,2)
 | 
|---|
| 72 | OTEX K PS,SSFIEN,SSF,MO Q
 | 
|---|
| 73 |  ;
 | 
|---|
| 74 | SSF2HP ;HELP
 | 
|---|
| 75 |  ;
 | 
|---|
| 76 |  S PS=$P($G(^ONCO(165.5,D0,2)),U,1)
 | 
|---|
| 77 |  Q:PS=""
 | 
|---|
| 78 |  S MO=$$HIST^ONCFUNC(D0)
 | 
|---|
| 79 |  ;
 | 
|---|
| 80 |  S SSFIEN=$S($D(^ONCO(164.52,"C",PS_"-2")):$O(^ONCO(164.52,"C",PS_"-2",0)),1:1)
 | 
|---|
| 81 |  ;
 | 
|---|
| 82 |  ;Malignant Melanoma of Skin, Vulva, Penis, Scrotum
 | 
|---|
| 83 |  I $$MELANOMA^ONCOU55(D0) D
 | 
|---|
| 84 |  .S MELIEN=$O(^ONCO(164.52,"B","ULCERATION",0))
 | 
|---|
| 85 |  .I $E(PS,3,4)=44 S SSFIEN=MELIEN Q
 | 
|---|
| 86 |  .I $E(PS,3,4)=51 S SSFIEN=MELIEN Q
 | 
|---|
| 87 |  .I $E(PS,3,4)=60 S SSFIEN=MELIEN Q
 | 
|---|
| 88 |  .I PS=67632 S SSFIEN=MELIEN Q
 | 
|---|
| 89 |  ;
 | 
|---|
| 90 |  ;Hodgkin and Non-Hodgkin Lymphomas of All Sites
 | 
|---|
| 91 |  I $$LYMPHOMA^ONCFUNC(D0) S SSFIEN=$O(^ONCO(164.52,"B","SYSTEMIC SYMPTOMS AT DIAGNOSIS",0))
 | 
|---|
| 92 |  ;
 | 
|---|
| 93 |  ;Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum
 | 
|---|
| 94 |  ;Kaposi Sarcoma of All Sites
 | 
|---|
| 95 |  I (MO=97003)!(MO=97013)!($E(MO,1,4)=9140) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
 | 
|---|
| 96 |  ;
 | 
|---|
| 97 |  ;Hematopoietic, Reticuloendothelial, Immunoproliferative, and
 | 
|---|
| 98 |  ;Myeloproliferative Neoplasms
 | 
|---|
| 99 |  I (MO'<97310)&(MO'>99899) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
 | 
|---|
| 100 |  ;
 | 
|---|
| 101 |  ;Retinoblastoma
 | 
|---|
| 102 |  I $E(MO,1,3)=951 S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
 | 
|---|
| 103 |  ;
 | 
|---|
| 104 |  W !," SITE-SPECIFIC FACTOR 2 for " D
 | 
|---|
| 105 |  .I MO=97003 W "MYCOSIS FUNGOIDES of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q
 | 
|---|
| 106 |  .I MO=97013 W "SEZARY SYNDROME of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q
 | 
|---|
| 107 |  .I $E(MO,1,3)=951 W "RETINOBLASTOMA of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q
 | 
|---|
| 108 |  .I $$MELANOMA^ONCOU55(D0),($E(PS,3,4)=44)!($E(PS,3,4)=51)!($E(PS,3,4)=60)!(PS=67632)!($E(PS,3,4)=69) W "MALIGNANT MELANOMA of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q
 | 
|---|
| 109 |  .I $E(MO,1,4)=9140 W "KAPOSI SARCOMA of ALL SITES" Q
 | 
|---|
| 110 |  .I $$LYMPHOMA^ONCFUNC(D0) W "HODGKIN AND NON-HODGKIN LYMPHOMAS of ALL SITES" Q
 | 
|---|
| 111 |  .I (MO'<97310)&(MO'>99899) W $P(^ONCO(169.3,MO,0),U,1)," (",$P(^ONCO(169.3,MO,0),U,2),")" Q
 | 
|---|
| 112 |  .W $P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")"
 | 
|---|
| 113 |  W !," ",$P(^ONCO(164.52,SSFIEN,0),U,1)
 | 
|---|
| 114 |  ;S SSF=0 F  S SSF=$O(^ONCO(164.52,SSFIEN,1,SSF)) Q:SSF'>0  D
 | 
|---|
| 115 |  ;.W " ",$P(^ONCO(164.52,SSFIEN,1,SSF,0),U,1)_"  "_$P(^ONCO(164.52,SSFIEN,1,SSF,0),U,2),!
 | 
|---|
| 116 |  K PS,SSFIEN,SSF,MO Q
 | 
|---|